SLNO has been in the news 321% more than usual
Mar 16, 2026, 2:32 PM
15.69%
What does SLNO do
Soleno Therapeutics, a clinical-stage biopharmaceutical company based in Redwood City, California, focuses on developing novel therapeutics for rare diseases, notably DCCR for Prader-Willi syndrome. DCCR, a once-daily oral tablet, recently completed Phase 3 trials and has received Fast-Track and orphan designations in the U.S. and EU.
SLNO has been in the news recently: DJS Law Group and the Schall Law Firm have announced a class action lawsuit against Soleno Therapeutics, Inc. for allegedly making misleading statements regarding its securities between March 26 and November 4, 2025. Additionally, Robbins Geller is inviting investors during the same period to apply to lead the lawsuit by May 5, 2026.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.